These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35181864)

  • 1. High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV.
    Sasaki H; Miyata N; Yoshimura Y; Tachikawa N
    Infection; 2022 Jun; 50(3):771-774. PubMed ID: 35181864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.
    Taha Y; Wardle H; Evans AB; Hunter ER; Marr H; Osborne W; Bashton M; Smith D; Burton-Fanning S; Schmid ML; Duncan CJA
    Ann Clin Microbiol Antimicrob; 2021 Dec; 20(1):85. PubMed ID: 34969393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. REGN-COV2 antibody cocktail in patients with SARS-CoV-2: Observational study from a single institution in Japan.
    Sakurai A; Marshall S; Ogasawara T; Ogasawara T; Aoka Y; Sakura H; Uchigata Y; Ogawa T
    J Infect Chemother; 2022 Jul; 28(7):943-947. PubMed ID: 35414436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
    Weinreich DM; Sivapalasingam S; Norton T; Ali S; Gao H; Bhore R; Musser BJ; Soo Y; Rofail D; Im J; Perry C; Pan C; Hosain R; Mahmood A; Davis JD; Turner KC; Hooper AT; Hamilton JD; Baum A; Kyratsous CA; Kim Y; Cook A; Kampman W; Kohli A; Sachdeva Y; Graber X; Kowal B; DiCioccio T; Stahl N; Lipsich L; Braunstein N; Herman G; Yancopoulos GD;
    N Engl J Med; 2021 Jan; 384(3):238-251. PubMed ID: 33332778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melatonin and REGN-CoV2 combination as a vaccine adjuvant for Omicron variant of SARS-CoV-2.
    Haskologlu IC; Erdag E; Sayiner S; Abacioglu N; Sehirli AO
    Mol Biol Rep; 2022 May; 49(5):4061-4068. PubMed ID: 35389130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of human monoclonal antibodies with neutralizing activity to a broad spectrum of SARS-CoV-2 viruses including the Omicron variants.
    Ueno M; Iwata-Yoshikawa N; Matsunaga A; Okamura T; Saito S; Ashida S; Yoshida I; Nagashima M; Asakura H; Yaoita Y; Suzuki J; Sadamasu K; Yoshimura K; Kutsuna S; Shiwa-Sudo N; Nagata N; Suzuki T; Suzuki A; Okamoto M; Kimura M; Ohmagari N; Miura R; Ishizaka Y
    Antiviral Res; 2022 May; 201():105297. PubMed ID: 35341809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of casirivimab/imdevimab administration in a SARS-CoV-2 positive maintenance dialysis patient in Japan.
    Terakawa K; Katagiri D; Shimada K; Sato L; Takano H
    CEN Case Rep; 2022 Aug; 11(3):328-332. PubMed ID: 35000134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups.
    Narasimhan M; Mahimainathan L; Araj E; Clark AE; Markantonis J; Green A; Xu J; SoRelle JA; Alexis C; Fankhauser K; Parikh H; Wilkinson K; Reczek A; Kopplin N; Yekkaluri S; Balani J; Thomas A; Singal AG; Sarode R; Muthukumar A
    J Clin Microbiol; 2021 Jun; 59(7):e0038821. PubMed ID: 33827901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
    Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
    Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
    Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific and neutralizing antibodies in recovered COVID-19 patients.
    Chansaenroj J; Yorsaeng R; Puenpa J; Wanlapakorn N; Chirathaworn C; Sudhinaraset N; Sripramote M; Chalongviriyalert P; Jirajariyavej S; Kiatpanabhikul P; Saiyarin J; Soudon C; Thienfaidee O; Ayuthaya TPN; Brukesawan C; Intharasongkroh D; Chaiwanichsiri D; Issarasongkhram M; Kitphati R; Mungaomklang A; Thitithanyanont A; Nagavajara P; Poovorawan Y
    PLoS One; 2022; 17(4):e0267102. PubMed ID: 35446889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical discovery and development of the casirivimab + imdevimab cocktail for the treatment of novel coronavirus infection: the rise and fall.
    Tuccori M; Convertino I; Ferraro S; Cappello E; Valdiserra G; de Luca G; Franchini M; Focosi D
    Expert Opin Drug Discov; 2022 Jun; 17(6):531-546. PubMed ID: 35361043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together.
    Zhang L; Poorbaugh J; Dougan M; Chen P; Gottlieb RL; Huhn G; Beasley S; Daniels M; Ngoc Vy Trinh T; Crisp M; Freitas JJ; Vaillancourt P; Patel DR; Nirula A; Kallewaard NL; Higgs RE; Benschop RJ
    Front Immunol; 2021; 12():790469. PubMed ID: 34956222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters.
    Baum A; Ajithdoss D; Copin R; Zhou A; Lanza K; Negron N; Ni M; Wei Y; Mohammadi K; Musser B; Atwal GS; Oyejide A; Goez-Gazi Y; Dutton J; Clemmons E; Staples HM; Bartley C; Klaffke B; Alfson K; Gazi M; Gonzalez O; Dick E; Carrion R; Pessaint L; Porto M; Cook A; Brown R; Ali V; Greenhouse J; Taylor T; Andersen H; Lewis MG; Stahl N; Murphy AJ; Yancopoulos GD; Kyratsous CA
    Science; 2020 Nov; 370(6520):1110-1115. PubMed ID: 33037066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
    Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
    MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Total escape of SARS-CoV-2 from dual monoclonal antibody therapy in an immunocompromised patient.
    Jaki L; Weigang S; Kern L; Kramme S; Wrobel AG; Grawitz AB; Nawrath P; Martin SR; Dähne T; Beer J; Disch M; Kolb P; Gutbrod L; Reuter S; Warnatz K; Schwemmle M; Gamblin SJ; Neumann-Haefelin E; Schnepf D; Welte T; Kochs G; Huzly D; Panning M; Fuchs J
    Nat Commun; 2023 Apr; 14(1):1999. PubMed ID: 37037847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.
    Nomura T; Kitagawa H; Kakimoto M; Kaiki Y; Nazmul T; Miyamori D; Omori K; Shigemoto N; Ito M; Sakaguchi T; Ohge H
    J Infect Chemother; 2022 Jul; 28(7):912-917. PubMed ID: 35370078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.